Beijing Northland Biotech. Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2012
NCT01548378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing Northland Biotech. Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

nl003 (4 trials)

oprelvekin (Neumega) (1 trial)

Drugs in Phase 2 Trials (1)

inactivated influenza vaccine (2 trials)

Drugs in Phase 1 Trials (1)

thymosin beta-4 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 3)

Ischemia (Phase 3)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Thrombocytopenia (Phase 3)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 4